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Ulnar sensory-motor amplitude ratio: 
a new tool to differentiate  
ganglionopathy from polyneuropathy
Razão de amplitude sensitivo-motora ulnar: novo parâmetro  
para diferenciar ganglionopatia de polineuropatia
Raphael Ubirajara Garcia, João Adilson Gama Ricardo, Cassiana Abreu Horta, Solange Garcia Garibaldi, 
Anamarli Nucci, Marcondes Cavalcante França Junior
Ganglionopathies (GNP), also known as sensory neuronop-
athies, are a group of conditions characterized by primary and 
selective damage to the dorsal root ganglia (DRG) of the spinal 
cord and sensory nuclei of the brainstem1,2. The etiologies are di-
verse and include immune-mediated diseases, vitamin deficien-
cies, drug toxicity, paraneoplastic syndromes and genetic causes, 
but many patients are yet defined as idiopathic1,2. The clinical 
presentation is characterized by diffuse, often asymmetric, sen-
sory deficits and marked ataxia due to loss of proprioception1,2.
In neurological practice, it is important to differenti-
ate GNP from polyneuropathies (PNP) because the etiolo-
gies, therapeutic strategies and prognosis are often diverse3. 
Clinically, GNP can be distinguished from PNP due to a pure-
ly sensory dysfunction and the absence of length-dependent 
gradient of involvement. Often it is not possible to define a 
clear pattern of symmetry or predominant distal involvement 
(either by clinical or electrophysiological criteria), making it 
difficult to distinguish a GNP from a sensory PNP. 
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ABSTRACT
The objective of this study was to evaluate if the ratio of ulnar sensory nerve action potential (SNAP) over compound muscle action potential 
(CMAP) amplitudes (USMAR) would help in the distinction between ganglionopathy (GNP) and polyneuropathy (PNP). Methods: We reviewed 
the nerve conductions studies and electromyography (EMG) of 18 GNP patients, 33 diabetic PNP patients and 56 controls. GNP was defined 
by simultaneous nerve conduction studies (NCS) and magnetic resonance imaging (MRI) abnormalities. PNP was defined by usual clinical 
and NCS criteria. We used ANOVA with post-hoc Tukey test and ROC curve analysis to compare ulnar SNAP and CMAP, as well as USMAR in 
the groups. Results: Ulnar CMAP amplitudes were similar between GNP x PNP x Controls (p=0.253), but ulnar SNAP amplitudes (1.6±3.2 x 
11.9±9.1 x 45.7±24.7) and USMAR values (0.3±0.3 x 1.5±0.9 x 4.6±2.2) were significantly different. A USMAR threshold of 0.71 was able to dif-
ferentiate GNP and PNP (94.4% sensitivity and 90.9% specificity). Conclusions: USMAR is a practical and reliable tool for the differentiation 
between GNP and PNP.
Key words: clinical neurophysiology, ganglionopathy, polyneuropathy, sensory neuronopathy, ulnar nerve.
RESUMO
O objetivo deste estudo foi avaliar se a razão entre as amplitudes dos potenciais de ação sensitivo (SNAP) e motor (CMAP) do nervo ulnar 
(USMAR) auxiliaria na distinção entre ganglionopatia (GNP) e polineuropatia (PNP). Métodos: Revisamos os estudos de neurocondução e ele-
tromiografia de 18 pacientes com GNP, 33 com PNP diabética e 56 controles. GNP foi definida pela presença simultânea de anormalidades na 
neurocondução e na ressonância magnética cervical. PNP foi definida por critérios clínicos e neurofisiológicos usuais. Usamos o teste ANOVA 
com Tukey post-hoc e análise da curva ROC para comparar o SNAP e CMAP ulnares, assim como o USMAR entre os grupos. Resultados: As 
amplitudes dos CMAPs ulnares foram similares entre GNP x PNP x Controles (p=0,253), mas as amplitudes dos SNAPs ulnares (1,6±3,2 x 
11,9±9,1 x 45,7±24,7) e os valores de USMAR (0,3±0,3 x 1,5±0,9 x 4,6±2,2) foram significativamente diferentes. Um corte de 0,71 para a US-
MAR foi capaz de diferenciar GNP de PNP (sensibilidade de 94,4% e especificidade de 90,9%). Conclusões: A USMAR é um parâmetro útil e 
confiável para o diagnóstico diferencial entre GNP e PNP.
Palavras-Chave: neurofisiologia clínica, ganglionopatia, polineuropatia, neuronopatia sensitiva, nervo ulnar.
466 Arq Neuropsiquiatr 2013;71(7):465-469
Nerve conduction studies (NCS) are able to evaluate sepa-
rately peripheral motor and sensory fibers. This helps to de-
termine the relative proportion of sensory over motor impair-
ment in peripheral nervous system diseases, and might prove 
useful to separate GNP from PNP4. In this setting, we hypoth-
esized that the ratio of the ulnar sensory nerve action potential 
(SNAP) amplitude divided by its compound muscle action po-
tential (CMAP) amplitude would be a good parameter to assist 
in this differentiation. We have then proceeded with this inves-
tigation by reviewing and comparing NCS in a sample of pa-
tients with GNP, length-dependent PNP and healthy controls.
METHODS
Subjects
We reviewed the electrodiagnostic studies of 107 subjects: 
18 patients with GNP, 33 patients with PNP, and 56 normal 
controls. All subjects were evaluated by clinical neurophysi-
ologists from the Department of Neurology of the University 
of Campinas (UNICAMP) between 1998 and 2011. The study 
was approved by our institution Ethics Committee, and a 
written informed consent was obtained from all participants.
Inclusion criteria
GNP
 The diagnosis of GNP was set when we could demon-
strate simultaneous damage both to central and peripheral 
extensions of DRG5,6. This was established by a combination 
of electrophysiological and spinal cord magnetic resonance 
imaging (MRI) criteria: (1) NCS showed widespread reduc-
tion of SNAP amplitudes (in a sural nerve and at least one 
other sensory nerve of the upper limbs) combined with nor-
mal sensory conduction velocities, motor NCS and elec-
tromyography (EMG); (2) cervical spinal cord MRI showed 
hyperintense T2 lesions in the dorsal funiculi. Each GNP pa-
tient presented sensory ataxia and preserved motor strength. 
PNP
The diagnosis of PNP was defined by NCS and clinical pre-
sentation. The NCS required at least one abnormality (potential 
amplitude, conduction velocity or distal latency) on at least two 
of the following nerves: median motor, peroneal motor, median 
sensory and sural. The clinical presentation required at least one 
abnormality along muscle strength, tendon reflexes, distal sen-
sation or autonomic dysfunction judged to be due to diabetic 
polyneuropathy7,8. All patients in this group had diabetes melli-
tus, but no other possible etiologies for PNP. These were exclud-
ed through anamnesis and extensive laboratory work-up8.
Control group
This group included only asymptomatic subjects with 
normal neurological examination, NCS and EMG8. 
Exclusion criteria
Patients with clinical or electrodiagnostic evidence of 
brachial plexopathy, C8-T1 radiculopathy or ulnar mononeu-
ropathy were not included in our study9. 
Electrophysiology
NCS and EMG were performed using Nihon Kohden de-
vices model MEB-9200J or Neuropack 2. All subjects had skin 
temperature maintained above 30ºC.
Ulnar sensory conduction studies were performed anti-
dromically, with ring surface electrodes recording from the right 
fifth finger and stimulation at the right wrist at a distance of 
100–140 mm from the active recording electrode. Stimulations 
were repeated 3–10 times to assure supramaximal stimulation, 
and the highest possible SNAP amplitude was registered.
Ulnar motor conduction studies were performed by re-
cording with surface electrodes on the abductor digiti min-
imi muscle of the right hand and stimulating at the wrist, 
40–70 mm away from the active recording surface electrode. 
Stimulations were repeated 3–10 times to assure supramaxi-
mal stimulation, and the highest CMAP amplitude was re-
corded. Responses obtained by more proximal stimulations 
were not considered in the study.
Additional NCS and EMG were performed to assess mo-
tor impairment or length-dependent gradient of involve-
ment according to inclusion and exclusion criteria described 
above. Those additional studies are not reported here.
Ulnar sensory-motor amplitude ratio (USMAR) was cal-
culated by dividing the ulnar SNAP amplitude (uV) by the 
distal ulnar CMAP amplitude (mV) for each subject.
Statistical analysis
 Demographic and NCS data of patients and controls 
are detailed with descriptive statistics. We compared the 
ages and the gender distribution in the three groups using 
ANOVA and Pearson’s chi-square tests, respectively. Ulnar 
SNAPs, ulnar CMAPs and USMAR values were compared in 
the GNP, PNP and control groups using ANOVA, with post-
hoc Tukey test for the USMAR values. We used a ROC curve 
to assess the usefulness of USMAR in the differentiation be-
tween GNP and PNP. Level of significance was set at α=0.05 
for all comparisons. Statistical analyses were performed 
with SYSTAT v9.0 (San Jose, CA) and SPSS v17 (Chicago, IL) 
softwares.
RESULTS
Group characteristics
The groups were similar in respect to gender distribution 
and mean age (p=0.108 and 0.06, respectively) (Table). In the 
PNP group, 32 out of 33 patients had reduced or absent ankle 
jerk, 28 had impaired vibration sensation at the hallucis and 2 
had gait instability.
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SNAP, CMAP and USMAR distribution
No significant difference was observed regarding the 
CMAP amplitudes of the ulnar nerve (p=0.253). We found 
significant differences between ulnar SNAP amplitudes and 
USMAR values among each of the three groups (p<0.001 and 
p<0.001, respectively) (Table). As expected, the lowest mean 
USMAR was observed in the GNP group, and the highest in 
the control group (Fig 1).
ROC curve
The area under the ROC curve was 0.929, showing that 
USMAR was able to differentiate both groups (Fig 2). A 
cutoff of 0.71 for USMAR presented the best profile to dis-
criminate between GNP and PNP (94.4% sensitivity and 
90.9% specificity).
DISCUSSION
GNP are a distinctive group of peripheral nervous system 
diseases and may be the first manifestation of systemic dis-
orders, such as cancer and Sjögren’s syndrome10,11. In clinical 
practice, GNP must be differentiated from sensory PNP, but 
this is not always a simple task. The hallmarks of GNP — dis-
proportionate sensory involvement and multifocal distribu-
tion of deficits — are often difficult to determine either by 
clinical or electrophysiological criteria. Sometimes, additional 
investigation such as spinal cord MRI, skin biopsy with epider-
mal nerve fiber density evaluation or even dorsal root ganglia 
biopsy is needed to reach the correct diagnosis6,12-14. Although 
valuable, some of these tests are expensive, invasive and time-
consuming. Therefore, other diagnostic tools are needed to dif-
ferentiate GNP and PNP.
Camdessanché et al. investigated whether SNAP ampli-
tudes of the median, ulnar, radial, sural and superficial pe-
roneal nerves would individually enable the distinction be-
tween GNP and PNP3. They found that nerves in the upper 
limbs are significantly more compromised in GNP, but using 
different thresholds to separate GNP and PNP sensitivity and 
specificity values ranged between 70 and 85%3. This motivat-
ed us to investigate other parameters derived from NCS that 
might work better.
Table. Demographic and neurophysiological data of the subjects included in the study.
GNP
(n=18)
PNP
(n=33)
Controls
(n=56) p-value*
Age (mean±SD, years) 53.0±2.7 56.9±7.0 52.0±11.4 0.06
Gender (M:F) 10:8 21:12 23:33 0.11
Ulnar SNAP amplitude (mean±SD, µV) 1.6±3.2 11.9±9.1 45.7± 24.7 <0.001
Ulnar CMAP amplitude (mean±SD, mV) 12.0±6.2 9.0±2.6 9.3±1.6 0.33
USMAR (mean±SD) 0.3±0.3 1.5±0.9 4.6±2.2 <0.001
*ANOVA p-values; GNP: ganglionopathies; PNP: polyneuropathies; SD: standard deviation; M: male; F: female; SNAP: sensory nerve action potential; 
CMAP: compound muscle action potential; USMAR: ulnar sensory-motor amplitude ratio.
Fig 2. ROC curve for the determination of threshold differentiating 
ganglionopathy from polyneuropathy.
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Fig 1. Box and Whiskers Plot showing the distribution of ulnar 
sensory-motor amplitude ratio values in the three groups. 
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